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Abstract
The aquaporins (AQPs) are plasma membrane water-transporting proteins. AQP4 is the principal
member of this protein family in the CNS, where it is expressed in astrocytes and is involved in
water movement, cell migration and neuroexcitation. AQP1 is expressed in the choroid plexus,
where it facilitates cerebrospinal fluid secretion, and in dorsal root ganglion neurons, where it
tunes pain perception. The AQPs are potential drug targets for several neurological conditions.
Astrocytoma cells strongly express AQP4, which may facilitate their infiltration into the brain, and
the neuroinflammatory disease neuromyelitis optica is caused by AQP4-specific autoantibodies
that produce complement-mediated astrocytic damage.
The aquaporins (AQPs) are a family of small, integral membrane transport proteins and their
primary function is to facilitate water movement across cell membranes in response to
osmotic gradients. The first member of this family, AQP1 (originally known as CHIP28),
was identified in erythrocytes in 1991 (REF. 1). This discovery led to homology cloning of
hundreds of AQP homologues from throughout the animal and plant kingdoms, as well as
from lower organisms2–5. In humans and rodents, there are 14 AQPs and at least eight of
these have been shown to transport water. A subset of AQPs called aquaglyceroporins,
which include AQP3, AQP7 and AQP9, also transport glycerol and, in the case of AQP9,
perhaps some small polar solutes6,7. Under some conditions, certain AQPs may transport
various gases (CO2, NH3, NO and O2), small solutes (H2O2) and ions (K+ and Cl–),
although the biological importance of gas, solute and ion transport by mammalian AQPs is
unclear8. In general, gas permeability is not limited by the intrinsic cell membrane
permeability but by diffusion in so-called ‘unstirred layers’ outside the membrane9. Water
transport is the primary function of the main AQPs in the CNS, namely AQP1 and AQP4.
This Review examines the expression and function of AQPs in the mammalian nervous
system, focusing on the cellular mechanisms by which AQPs affect CNS functions. In
addition, AQP-related CNS diseases — including neuromyelitis optica (NMO), involving
astrocyte damage that is mediated by AQP4-specific antibodies — and potential AQP-
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targeted therapeutics are discussed. AQPs are also expressed widely outside the nervous
system in epithelia, microvascular endothelia, epidermis, immune cells, adipocytes, skeletal
muscle and other tissues, and the reader is referred to recent reviews for more information
about these non-nervous system functions of AQPs and their underlying cellular
mechanisms2,3.
AQP structure
AQP monomers are ~30 kDa and, in general, contain six membrane-spanning helical
segments and two shorter helical segments that do not span the entire membrane10 (FIG. 1a).
The AQPs generally form stable tetramers in membranes, although each monomer contains
a separate water pore. High-resolution structural data show that the membrane-spanning
helical domains surround cytoplasmic and extracellular vestibules that are connected by a
narrow aqueous pore11 (FIG. 1b). Structural data and molecular dynamics simulations
suggest that water molecules move through this narrow aqueous pore and that steric and
electrostatic factors are responsible for the water selectivity of AQPs12,13. The pore is less
constricted in the aquaglyceroporins than in the water-selective AQPs (diameter of 3.4 Å
versus 2.8 Å, respectively) and is lined by more hydrophobic residues.
Interestingly, AQP4 can form crystal-like supramo-lecular assemblies in the plasma
membrane, which are called orthogonal arrays of particles (OAPs). OAPs have been
visualized by freeze-fracture electron microscopy in AQP4-transfected cells14 and have been
found in the brain and other tissues in wild-type but not Aqp4 deficient mice15. Labelling of
OAPs by AQP4-specific antibodies has allowed their visualization by immunogold electron
microscopy16,17 and, recently, by super-resolution fluorescence microscopy18 (FIG. 1c).
AQP4 is present as two major isoforms that are produced by alternative splicing: the
relatively long M1 isoform, which is generated by translation initiation at Met1, and a
shorter M23 isoform, which is generated by translation initiation at Met23 (FIG. 1a). The
M1 and M23 isoforms of AQP4 associate in membranes as heterotetramers17,19,20 and
aggregate into OAPs through M23–M23 interactions, involving hydrophobic residues just
downstream of Met23 (REF. 21). The biological importance of OAP formation by AQP4 is
unknown. It has been speculated that OAPs enhance water permeability22 and might be
involved in cell–cell adhesion23, but these hypotheses have been refuted
experimentally24,25. OAPs might also be involved in AQP4 polarization in astrocyte foot
processes (see below)26. Interestingly, as discussed later, AQP4 OAPs have a crucial role in
the pathophysiology of NMO.
AQP expression in the nervous system
AQP expression has been studied more intensively in the CNS and sensory organs than in
the peripheral and enteric nervous systems. The expression pattern of AQPs in the nervous
system is summarized in FIG. 2.
CNS
AQP4 is the most abundant water channel in the brain27, spinal cord28 and optic nerve29.
Although AQP4 is widely expressed in the astrocyte cell plasma membrane, it is primarily
localized to specific regions, such as astrocyte foot processes17,30. This polarized expression
of AQP4 may result from intracellular interactions between this channel and α-syntrophin31
or through extracellular AQP4 interactions with agrin32; like AQP4, α-syntrophin and agrin
show polarized expression in astrocyte foot processes33. Intercellular astrocyte contacts with
endothelial and pial cells may also be important for AQP4 polarization, as loss of these
contacts abolishes the polarized expression pattern34–36. It has been suggested that OAPs
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facilitate AQP4 polarization, because a single link is required to tether an entire AQP4 array
to the plasma membrane, whereas scattered AQP4 tetramers each require a tether26.
In the brain, AQP4 is primarily localized to the subpial astrocyte processes that form the
glial-limiting membrane (which acts as the CNS–cerebrospinal fluid (CSF) interface), the
perivascular astrocyte endfeet (which are found at the CNS–blood interface) and the
basolateral membrane of ependymal cells and subependymal astrocyte processes (which
form the CNS–CSF interface)17,30. This pattern of AQP4 expression at the borders between
the brain and major water-containing compartments suggests that AQP4 facilitates the flow
of water into and out of the brain. In parts of the brain, including the circumventricular
organs (which lack a blood–brain barrier (BBB))17,30 and the hippocampus37, AQP4 is
expressed throughout the astrocyte cell plasma membrane. The absence of perivas-cular
astrocyte foot processes in the circumventricular organs may explain the relatively non-
polarized distribution of AQP4 in these structures. In the hippocampus, AQP4 is expressed
within CA1 and the dentate gyrus, where it may facilitate the rapid water fluxes that are
required for maintaining K+ homeostasis during electrical activity38–40. A detailed
discussion of the role of AQP4 in K+ homeostasis is given below.
AQP1 is found in the ventricular-facing cell plasma membrane of choroid plexus epithelial
cells41,42, suggesting a role for this channel in CSF secretion. AQP1 is also expressed in
vascular endothelial cells throughout the body but is notably absent in the cerebrovascular
endothelium41, except in circumventricular organs43. Cerebrovascular endothelial cells
express AQP1 in culture44 and when the BBB is disrupted in malignant brain tumours45.
Co-culture with astrocytes suppresses Aqp1 mRNA expression in primary brain microvessel
endothelial cells44. These findings suggest that interactions between astrocyte foot processes
and endothelial cells inhibit endothelial AQP1 expression.
AQP9 is weakly expressed in the brain46, but its localization is unclear because the available
antibodies against this channel exhibit poor specificity. Expression of AQP9 has been
reported in neurons of the substantia nigra, tanycytes and some astrocytes.
In the spinal cord, AQP4 is primarily localized in perivascular astrocyte foot processes and
in the glial-limiting membrane, AQP1 is expressed in processes of non-myelinated neurons
in the dorsal horns, and AQP9 may be expressed in spinal cord radial astrocytes and in the
glial-limiting membrane28,47. As in the brain and spinal cord, the optic nerve expresses
AQP4 primarily in perivascular astrocyte foot processes and in the glial-limiting
membrane29. AQP4 is also expressed in astrocyte processes in regions of the CNS without a
BBB, including the pre-laminar optic nerve head48, the circumventricular organs49 and the
root entry zones in the spinal cord50. This CNS AQP4 pool is thus exposed to the periphery
and may be the initial target of circulating AQP4-specific antibodies in NMO (discussed
below)51,52.
Peripheral nervous system
In dorsal root ganglia, AQP1 colocalizes with substance P and the capsaicin receptor
TRPV1 (transient receptor potential cation channel subfamily V member 1) in a
subpopulation of neuronal C-fibres47,53. AQP1 is also expressed in neurons of the trigeminal
ganglion that mediate nociception from the head. Consistent with these observations, AQP1
is expressed in the dorsal horns of the spinal cord, specifically in laminae associated with
nociception28. There are a few isolated reports of AQP1 expression in other parts of the
peripheral nervous system, including in the sciatic nerve28,54 and the periodontal Ruffini
mechanoreceptors55.
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Sensory organs
AQP4 is expressed in retinal glia (which are called Müller cells)56, supporting cells in
olfactory epithelium57, and Claudius cells, Hensen cells and inner sulcus cells of the organ
of Corti in the inner ear58; however, it is absent from excitable cells in these tissues. This is
an analogous situation to that in the CNS, where AQP4 is found in astrocytes but not in
neurons. Of note, AQP1 is also expressed in the fibrocytes of the spiral ligament in the inner
ear58.
Various AQPs can be detected in the eye. AQP1 is expressed in the corneal endothelium,
keratocytes and the ciliary epithelium. AQP4 is expressed in the ciliary epithelium. By
contrast, AQP3 is expressed in the conjunctival epithelium and, together with AQP5, the
corneal epithelium. Finally, AQP0 expression is detectable in lens fibre cells. This
expression pattern suggests that AQPs are involved in intraocular pressure regulation,
corneal and lens transparency, and corneal and conjunctival barrier function (see REF. 59
and papers cited therein for further description of ocular AQP expression and functional data
from Aqp knockout mice).
Enteric nervous system
The enteric nervous system comprises neurons and glia in the submucosal and myenteric
plexuses, which regulate solute absorption and gastrointestinal motility. AQP1 has been
detected in glia in human oesophageal neurons54 and rat ileal neurons60 in the submucosal
and myenteric plexuses, as well as in sub-mucosal neurons of sheep duodenum61. AQP4 has
been detected in rat and mouse myenteric and submucosal neurons62. Increased AQP1
expression in ileal neurons of diabetic rats has suggested that AQP1 may be involved in
diabetic gastrointestinal dysfunction63. No functional data exist for the involvement of
AQP1 or AQP4 in mucosal solute transport or gastrointestinal motility.
Spine
The intervertebral disc consists of a gelatinous core, the nucleus pulposus, which acts as a
shock absorber and is surrounded by a tough annulus fibro-sus. AQP1 and AQP3 are
expressed in chondrocyte-like cells that reside within the nucleus pulposus64. As
dehydration of the nucleus pulposus is a characteristic feature of degenerated discs, it has
been suggested that AQPs might play a part in degenerative disc disease, which is a
common cause of back pain64. The expression of AQP9 in osteoclasts65 has suggested a role
for this channel in bone resorption and osteoporosis. However, no functional studies have
been conducted to test these ideas.
AQP functions in the nervous system
Knowledge of AQP functions in the nervous system is largely derived from experiments
subjecting Aqp knockout mice to different pathological conditions, as to date there are no
selective, non-toxic AQP inhibitors, and humans with loss-of-function mutations in AQP4
have not been identified. At least three groups have generated Aqp4 deficient mice (BOX 1)
and identified major roles for AQPs in facilitating water movement into and out of the CNS,
astrocyte migration and neuroexcitation. When interpreting the mouse data, some
differences between the CNS of rodents and primates should be noted. Neurons outnumber
astrocytes by 3 to 1 in mouse and rat cerebral cortex, but in human cerebral cortex,
astrocytes outnumber neurons by 1.4 to 1 (REF. 66). Furthermore, AQP1, which is not
expressed in mouse astrocytes in vivo, has been detected in some astrocytes in monkey
brain67. Together, these observations suggest that AQPs may have more important roles in
the primate CNS than in the rodent CNS.
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Box 1
Aquaporin 4 knockout mice
The first aquaporin 4 (Aqp4) knockout mouse line was generated by Verkman’s group in
San Francisco, USA145. This line was followed by an Aqp4 knockout mouse line
generated by Hu’s group in Nanjing, China146 and, later, a line made by the group of
Ottersen and Nagelhus in Oslo, Norway; in these latter mice, Aqp4 could be
conditionally deleted in glia only, thereby preserving AQP4 expression in peripheral
organs72. In general, Aqp4 knockout mice have normal brain vascular anatomy (San
Francisco)79, gross appearance, neuronal, astrocyte and oligodendrocyte characteristics
and blood–brain barrier (BBB) integrity (San Francisco and Oslo)72,147. Indeed, the
findings from the San Francisco and Oslo Aqp4 knockout mice are remarkably similar.
The Nanjing Aqp4 knockout mice have marked abnormalities including disruption of the
BBB, which allows large proteins to pass through it, and therefore data from these mice
should be interpreted with caution146. Compared with wild-type mice, Aqp4 knockout
mice show mild extracellular space volume expansion (San Francisco)148–150, slightly
increased brain water content (San Francisco and Oslo)27,72, reduced perivascular
expression of α-syntrophin and dystrophin (Oslo)151 and reduced expression of
excitatory amino acid transporter 2 (EAAT2; also known as GLT1 and SLC1A2), which
is a glutamate transporter (Nanjing)152. Isolated reports have shown that Aqp4 knockout
mice have reduced neuroinflammation (San Francisco)153, impairment of long-term
potentiation (San Francisco)154, impairment in astrocyte cell volume regulation (Oslo)155
and a series of neurochemical, neuronal and behavioural abnormalities (Nanjing)156,157.
It has also been suggested that AQP4 may facilitate the uptake of amyloid-β into
astrocytes (Nanjing)158 and AQP9 may facilitate the uptake of MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) into substantia nigra neurons (Oslo)159. In general,
studies conducted in knockout mice are potentially confounded by altered expression of
many genes. Thus, it is not known whether the apparent differences between Aqp4
knockout and wild-type mice are a primary or secondary consequence of Aqp4 deletion.
Water movement
The intracranial cavity in adults comprises several compartments (that is, blood, CSF and
brain parenchyma intracellular and interstitial spaces) and is surrounded by the non-
distensible skull. Water flows between these compartments in response to osmotic and
hydrostatic forces. Although water molecules can cross the cell plasma membrane directly
and perhaps to a small extent through some glucose transporters and ion channels68,69,
several studies support a major role for AQP4 in determining BBB water permeability.
Aqp4 deletion is associated with a sevenfold reduction in cell plasma membrane water
permeability in cultured astrocytes35 and a tenfold reduction in BBB water permeability in
mouse brain70. Reducing AQP4 protein expression with small interfering RNAs (siRNAs)
by 27% in the rat brain caused a 50% decrease in the apparent diffusion coefficient, which is
consistent with reduced astrocyte cell plasma membrane water permeability71.
Nevertheless, Aqp4 null mice have normal intracranial pressure27 and only slightly
increased total brain water content27,72. These findings suggest that AQP4 is not needed for
relatively slow water movements into and out of the brain that take place under normal
physiological conditions, as these can occur through AQP4-independent pathways. In CNS
diseases (such as brain injury, meningitis, brain tumours and hydrocephalus), the rates of
water flow into and out of the brain rise, causing increased intracranial pressure from excess
water accumulation in intracranial compartments. Increased intracranial pressure is
detrimental, as it causes brain ischaemia, herniation and, ultimately, brain death (for
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reviews, see REFS 73,74). AQP4 thus facilitates water transport into and out of the brain in
these CNS diseases.
Several descriptive studies show that changes in brain AQP4 expression correlate with the
amount of brain oedema in human and rodent diseases70,75–78, suggesting that this channel
has a role in brain oedema. However, the spatial and temporal patterns of AQP4 expression
are complicated, such that it is unclear from these studies whether increased AQP4
expression exacerbates brain oedema or facilitates oedema fluid clearance. AQP4 is
upregulated in cerebral contusion, bacterial meningitis and subarachnoid haemorrhage, thus
potentially amplifying its contribution to brain oedema formation or elimination70,75–78.
Studies of Aqp4 knock out in mouse models of various CNS diseases also support a role of
AQP4 in water transport. There is less brain oedema in Aqp4 knockout than in wild-type
mice after focal cerebral ischaemia, water intoxication72,79 or bacterial meningitis70. Mice
lacking α-syntrophin80 or dystrophin81, which show AQP4 mis-localization on the surface
of astrocytes, also develop less brain oedema than wild-type mice after water intoxication or
focal cerebral ischaemia. However, the presence of abnormalities in the brains of the α-
syntrophin knockout mice (which have swollen astrocyte endfeet)80 and dystrophin
knockout mice (which have open tight junctions, degenerating microvessels and swollen
astrocyte endfeet)82 confound the interpretation of these findings. Aqp4 null mice also
develop less spinal cord oedema after transient cord compression83. The mouse models of
water intoxication, focal cerebral ischaemia, bacterial meningitis and spinal cord
compression (which is associated with ischaemic cord damage) generate a blood–CNS
osmotic gradient from serum hypo-osmolality (in the case of water intoxication) or energy
failure (in the case of ischaemia and meningitis) that drives water flow from the blood into
the brain cells, causing cytotoxic oedema. These findings suggest that, in wild-type mice, the
excess water enters the CNS through AQP4 channels, with reduced water entry in Aqp4
knockout mice83 (FIG. 3). Reduced cytotoxic brain oedema (and downstream signalling) has
also been found in glia-specific Aqp4 knockout mice following water intoxication84, and
increased cytotoxic oedema was found in AQP4-overexpressing transgenic mice85. AQP4 is
thus the rate-limiting step for water flow from the blood into the CNS in diseases associated
with oedema in which the BBB is intact.
In models of disease involving BBB disruption, including brain tumour27, brain abscess86,
subarach-noid haemorrhage87 and status epilepticus88, Aqp4 null mice develop more brain
oedema than wild-type mice. Increased oedema in Aqp4 null mice was also seen after
contusion spinal cord injury89, which disrupts the blood–spinal cord barrier. Microinfusion
of saline directly into brain extracellular space (ECS) produced a greater increase in
intracranial pressure in Aqp4 knockout than in wild-type mice27. In these models,
hydrostatic forces drive water and solutes from the blood through the disrupted BBB into the
ECS independent of AQP4 (this is called vasogenic oedema). Although the rate of brain or
spinal cord water entry is similar in wild-type and Aqp4 null mice, the greater water
accumulation in the latter suggests that elimination of vasogenic oedema fluid is AQP4-
dependent.
Two theories of AQP4-dependent vasogenic oedema fluid clearance from the CNS have
been proposed, and both involve AQP4-dependent transcellular water flow. In one theory,
water elimination occurs across three AQP4-rich interfaces (through the ependyma into the
ventricular CSF, the subpial astrocytes into the subarach-noid CSF and the BBB into the
blood) and is driven by hydrostatic pressure27 (FIG. 3). According to the other theory,
excess water flows through the brain parenchyma, transcellularly through AQP4, into
perivenous spaces and then along veins. The fluid is then eliminated into cervical lymphatics
and through arachnoid granulations into the blood90. A problem with both theories is that
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the flow of solute-free water through AQP4 would be opposed by the osmotic gradients
created between the intracellular and extracellular spaces as well as between the intracellular
space and the CSF.
AQP1 plays a part in CSF secretion and AQP4 in CSF absorption. CSF is secreted by the
choroid plexus and is absorbed primarily through arachnoid granulations into the venous
sinuses and by other routes such as transependymal flow into the brain. CSF secretion
involves the active transport of Na+ from the blood into the ventricles, which generates an
osmotic gradient that drives the flow of water. AQP1 is expressed in the apical (ventricular-
facing) surface of the choroid plexus epithelium41. Compared with wild-type mice, Aqp1
knockout mice have fivefold reduced osmotic water permeability in the choroid plexus and
50% lower intracranial pressure. The CSF secretion rate is reduced by only 25% in Aqp1
deficient mice compared with wild-type mice, which suggests that only part of CSF
secretion is AQP1-dependent and the rest is through non-AQP1-dependent pathways42. The
presence of AQP4 in ependymal cells and subependymal astrocytes is an important
determinant of CSF flow across the ventricle–brain interface. Indeed, reduced
transependymal CSF flow into the brain parenchyma and reduced CSF absorption across the
BBB into the blood may account for the sporadic hydrocephalus observed in Aqp4 null
mice91 and the accelerated progression of obstructive hydrocephalus in AQP4 deficiency
produced by cisternal kaolin injection92. The increased AQP4 expression observed in human
and rodent hydrocephalus78 may be a compensatory response to facilitate CSF elimination
through the transependymal route.
Astrocyte migration
An unexpected role for AQPs in cell migration was suggested in a study in which localized
micropipette delivery of Hg2+ or small polyethylene glycols impaired neutrophil motility,
perhaps by reducing water flow through AQP9 (REF. 93). Another study using Aqp1
knockout mice showed that microvascular endothelial cells from such animals migrated
more slowly than those from wild-type mice and, indeed, that the slower migration of these
cells accounted for the impaired angiogenesis observed in the knockout animals94. AQP-
facilitated cell migration was subsequently reported in a wide variety of immune, epithelial,
tumour and other cell types95. In a mouse model of tumour cell metastasis, AQP expression
in tumour cells was shown to increase their extravasation across blood vessels and their
local invasiveness96.
In migrating astrocytes, AQP4 expression mainly occurs at the leading edge of such cells
and hence is largely polarized97. Compared with astrocytes from wild-type mice, astrocytes
from Aqp4 knockout mice showed slowed migration in in vitro transwell and wound healing
assays, but they did not exhibit impairments in cell proliferation or adhesion. In vivo, glial
scar formation was impaired in Aqp4 knockout mice following stab injury97. In addition,
following injection into the brains of wild-type mice, fluorescently labelled wild-type
astrocytes migrated faster than fluorescently labelled Aqp4 deficient astrocytes98. AQP4-
dependent astrocyte migration may thus facilitate glial scar formation.
In one proposed mechanism for AQP-dependent astrocyte migration, AQP-facilitated water
transport at the leading edge of migrating astrocytes increases their lamellipodial extension
(FIG. 4a). According to this mechanism, actin depolymerization and/or active solute influx
in lamellipodia creates an osmotic gradient that drives water influx across the cell’s plasma
membrane. The resultant increase in hydrostatic pressure causes local expansion of the
plasma membrane, which is followed by actin re-polymerization to stabilize the cell
membrane protrusion. The observation that regional hydrostatic pressure changes within
cells do not equilibrate in the cytoplasm on scales of 10 microns and 10 seconds99 supports
the possibility of pressure-induced formation of localized cell membrane protrusions. In
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support of the idea that AQP-dependent water flow occurs into and out of migrating
astrocytes, the migration of such cells can be modulated by changes in extracellular
osmolality and transcellular osmotic gradients97,100, AQP expression increases the migration
in multiple cell types and with different AQPs, and AQP expression increases lamellipodial
ruffling and dynamics94,97. However, direct support of this proposed mechanism will
require measurement of water transport across lamellipodia in migrating cells. Alternative
potential mechanisms to explain AQP-dependent cell migration include AQP-dependent
changes in cell shape and volume during passage through tight environments and specific
interactions between AQPs and components of the cell locomotion machinery95,101.
Neuroexcitation
A role for AQP4 in neural signal transduction was first proposed following the observation
that deletion of α-syntrophin in mice is associated with severe hyperthermia-induced
seizures and prolonged K+ clearance40. Studies in knockout mice and brain slices have
confirmed that AQP4 is involved in neural signal transduction and have provided
mechanistic insights. Aqp4 deficient mice have an increased threshold for seizure initiation
with chemical102 or electrical38 stimulation and show prolonged seizure duration and altered
K+ reuptake kinetics38. In the intra- hippocampal kainic acid model of epileptogenesis,
Aqp4 knockout mice exhibit an increase in the frequency of spontaneous seizures during the
first week after status epilepticus103 (for a review of the role of AQP4 in seizures, see REF.
104).
With regard to neurosensory signal transduction, auditory signal-evoked responses are
impaired in Aqp4 knockout mice58. Sound waves displace the stereocilia of inner hair cells,
causing K+ flow from the endolymph into the hair cell and consequent depolarization.
Supporting cells take up K+ from the hair cells. Aqp4 knockout mice have mildly impaired
retinal function with reduced amplitude of b-waves (produced by bipolar cells), as detected
by electroretinography56, which has been interpreted as impaired coupling of bipolar cell
depolarization to Müller cell activation. Aqp4 knockout mice also have impaired olfaction,
as shown in behavioural studies and by reduced electro-olfactogram voltage responses to
odorants57.
Delayed K+ reuptake was initially demonstrated in α-syntrophin null mice40.
Microelectrode and fluorescence imaging studies in the brain in vivo and in brain slices of
Aqp4 deficient mice also showed slowed accumulation of K+ in the brain ECS during
neuroexcitation38,105 and slowed clearance of K+ from the ECS following neu-
roexcitation39,105. Slowed K+ clearance from the ECS could account for the various
neuroexcitation phenotypes, such as prolonged seizure duration, that are observed in Aqp4
knockout mice.
The mechanistic link between K+ reuptake by astro-cytes and AQP4 water permeability is
unclear. The ECS represents approximately ~20% of total brain volume106. K+ is released
into the ECS by neurons in response to membrane depolarization during neuroexcitation and
is mainly cleared through uptake by astrocytes, which involves the inwardly rectifying K+
channel Kir4.1 and other astrocyte K+ transporters (FIG. 4b). One hypothesis to explain K+–
water coupling is a functional interaction between AQP4 and Kir4.1 (REFS 40,107);
however, a patch-clamp study of astrocytes and Müller cells showed that AQP4 expression
did not affect Kir4.1 function108. An alternative possibility is that uptake of K+ following
neuroexcitation results in osmotic water influx by astrocytes and, consequently, ECS
shrinkage, which would maintain the electrochemical driving force for efficient K+ reuptake
(FIG. 4b). The reduction in astrocyte water permeability linked to AQP4 deficiency would
impair ECS contraction and hence slow K+ reuptake. This hypothesis, which is supported by
mathematical modelling109, is attractive because it relates the neuroexcitation phenotypes
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directly to AQP4-mediated water transport. Nonetheless, at this time, the possibility that the
neuroexcitation phenotypes resulting from the Aqp4 deficiency can be explained by altered
expression of genes other than Aqp4 cannot be excluded.
Aquaporin functions in the peripheral nervous system
Several studies have shown AQP1 expression in non-myelinated neurons in the dorsal root
ganglia and their projections in the dorsal horns of the spinal cord28,47,53 (FIG. 2). An initial
study reported that Aqp1 knockout mice showed reduced sensitivity for some painful stimuli
applied to the paws (thermal stimuli and capsaicin) but not others (mechanical stimuli and
formalin)53, suggesting that AQP1 has a role in the perception of pain. Another study,
however, found that Aqp1 deletion had no effects on pain perception44. A subsequent study
showed that Aqp1 knockout mice exhibit a selective reduction in thermal inflammatory- and
cold-induced pain and provided biophysical evidence for an interaction between AQP1 and
the voltage-gated Na+ channel NaV1.8 (REF. 110). A patch-clamp study showed that Aqp1
deficient dorsal root ganglion neurons exhibited reduced action-potential firing in response
to current injections, and experiments in the NaV1.8-expressing cell line ND7-23 showed
that AQP1 expression altered NaV1.8 frequency-dependent inactivation. A functional
interaction between AQP1 and an ion channel represents a mechanism of action for these
channels that is quite different from their typical role in water and small solute transport.
There are no functional data on the role of AQP1 in trigeminal ganglion neurons53 or in
Ruffini mechanoreceptors55 in which this channel is expressed.
Translational aspects of AQP neurobiology
AQPs expressed in the CNS are novel therapeutic targets for brain oedema and epilepsy, as
discussed above, and for NMO and astrocytomas, as discussed below.
Neuromyelitis optica
NMO is a rare inflammatory demy-elinating disease of the CNS that preferentially affects
the optic nerves and spinal cord52,111, and causes blindness, paralysis and death. It was
thought to be a variant of multiple sclerosis (MS) until 2004, when serum antibodies against
a perivascular brain antigen were detected in individuals with NMO but not in patients with
MS112; these antibodies were subsequently shown to be against AQP4 (REF. 113). AQP4-
specific antibodies are now widely used to diagnose NMO and distinguish it from MS.
AQP4-specific antibodies in NMO are predominantly of the immunoglobulin G1 (IgG1)
subtype and bind three-dimensional conformational epitopes on the extracellular loops of
AQP4, producing astrocyte damage by complement-dependent cytotoxicity (FIG. 5). The
AQP4-specific IgG epitopes appear to be located in all three extracellular loops of AQP4
(REFS 114–116). It was initially reported that AQP4-specific IgG binds to OAPs
exclusively117, but it is now known that AQP4-specific IgG binds to both individual AQP
tetramers and OAPs, although generally with higher affinity to OAPs118–120. AQP4-specific
IgG binding to AQP4, when assembled into OAPs, greatly increases complement activation
because of the multivalent binding characteristics of complement protein C1Q120. Binding
of AQP4-specific IgG does not alter AQP4 water permeability, the plasma membrane
AQP4-M1/AQP4-M23 isoform ratio or OAP assembly24. In cultured cells transfected with
Aqp4, AQP4-specific IgG binding causes AQP4 internalization118, but this is unlikely to
have a role in NMO because AQP4 internalization is not seen in primary astrocyte cultures
or in the mouse brain121.
When injected intracerebrally in mice, AQP4-specific IgG binds to AQP4, producing the
characteristic histolog-ical features of human NMO, including astrocyte damage,
perivascular deposition of activated complement proteins, leukocyte infiltration, myelin loss
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and neuronal cell death122. The inflammatory cells associated with NMO are primarily
granulocytes (neutrophils and eosinophils) and macrophages, with few lymphocytes,
whereas MS lesions are devoid of granulocytes but rich in lymphocytes and macrophages.
Current therapies for NMO target the immune response and/or the level of circulating
AQP4-specific IgG, and include general immunosuppres-sion, plasma exchange and anti-B
cell therapy111.
Although the discovery of AQP4-specific IgG has revolutionized our understanding of
NMO pathogenesis (FIG. 5) and has suggested novel therapeutic strategies, as discussed
below, major unanswered questions remain. Why are peripheral AQP4-expressing organs
not damaged by AQP4-specific IgG, how does peripherally produced AQP4-specific IgG
enter the CNS, why is there a predilection for the optic nerves and spinal cord and what
causes AQP4-specific IgG-seronegative NMO? The reader is referred to recent reviews for
further details on NMO pathogenesis mechanisms51,52,111.
Brain tumours
Astrocytomas are the most common primary brain tumours. They are histologically
classified into grades I–IV depending on malignancy, with grade IV astrocytomas
(glioblastoma multiforme or just glioblas-toma) being the most common. Even with
extensive surgical debulking, radiotherapy and chemotherapy, the median survival time for
individuals with glioblastoma is less than 1 year from diagnosis123. Glioblastoma cells are
difficult to eradicate because they infiltrate extensively into the surrounding brain,
precluding effective surgical excision. Following the initial observation of Saadoun et al.34
of strong AQP4 expression in astrocytomas, with the highest levels of this channel being
found in glioblas-tomas, several studies have reported similar findings124,125. Glioblastomas
sometimes also express AQP1 and AQP9 (REFS 45,126). The correlation between the level
of AQP expression in tumour cells and the amount of tumour oedema, as revealed by MRI,
has suggested the involvement of AQPs in tumour oedema127, although a more intriguing
idea is that AQPs facilitate tumour cell migration through the ECS, thus facilitating the
infiltration of such cells into the surrounding tissue128. The potential therapeutic
implications of tumour cell AQP expression include the use of AQP inhibitors to reduce
tumour cell infiltration and AQP4-targeted toxins to kill tumour cells.
Aquaporin-based therapeutics
There has been much speculation, but little progress, in the development of AQP-targeted
therapeutics for nervous system disorders129,130. Phenotype data from knockout mice and
basic physiological principles suggest the use of AQP4 water channel blockers to reduce
brain oedema in stroke, trauma and other disorders associated with a primary cytotoxic
response. There is also a good rationale for the development of AQP inhibitors to reduce the
migration and hence local invasion of astrocytoma tumour cells and perhaps to reduce glial
scarring and hence facilitate neuronal regeneration following stroke or trauma. AQP1
inhibitors may provide a non-narcotic approach to reduce nociception in certain types of
pain. Other proposed applications of AQP modulators — including accelerating brain water
clearance in vasogenic oedema, anti-epileptic action, anti-inflammatory action and others —
require further mechanistic understanding of AQP-dependent pathophysiology.
Limited progress has been made in AQP-targeted therapeutics. Sulfhydryl-reactive heavy
metal ions, such as mercury and gold, inhibit water permeability by several AQPs131;
however, they are not suitable for use in live cells because of their toxicity and generalized
protein reactivity. There have been isolated reports that anti-epileptics132, carbonic
anhydrase inhibitors133, 5-hydroxytryptamine agonists131, loop diuretics134,135, zinc136 and
other molecules137 have water channel inhibition action, although subsequent re-evaluation
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did not confirm water channel inhibition138. The reasons for slow progress in AQP inhibitor
discovery might include intrinsic poor ‘druggability’ of AQPs as targets for small molecules
and challenges in developing and carrying out robust high-throughput screens.
One area of AQP therapeutics in which progress has been made is in NMO, which, as
mentioned above, involves binding of pathogenic AQP4-specific autoanti-bodies to AQP4
on astrocytes, complement-dependent cytotoxicity and an inflammatory response. Biological
and small-molecule therapeutics have been developed that block AQP4-specific IgG binding
to AQP4 by targeting the extracellular surface of AQP4 (REFS 139,140). Of particular
interest is aquaporumab, a high-affinity monoclonal AQP4-specific antibody that has been
rendered non-pathogenic by mutation of its Fc region (BOX 2). Aquaporumab competes
with pathogenic AQP4-specific IgG for binding to AQP4, reducing NMO pathology in ex
vivo and in vivo NMO models139. Another approach involves IgG-selective enzymatic
deglycosylation (BOX 2), which neutralizes AQP4-specific IgG pathogenicity and produces
a therapeutic blocking antibody141.
Box 2
Aquaporin 4 ‘blocking therapy’ in neuromyelitis optica
An initiating step in producing astrocyte damage and an inflammatory reaction in
neuromyelitis optica (NMO) is the binding of the aquaporin 4 (AQP4)-specific
autoantibody, immunoglobulin G (IgG), to AQP4 on the plasma membrane of astrocytes.
The rationale of ‘blocking therapies’ under development for NMO is to prevent AQP4-
specific IgG binding to AQP4. In one form of blocking therapy, a non-pathogenic, high-
affinity AQP4-specific antibody (aquaporumab) was engineered. The figure (left panel)
shows that an IgG1 antibody is substantially larger than an AQP4 tetramer, and this
sterically limits the number of antibodies that can bind to such tetramers. A high-affinity
AQP4-specific IgG antibody was identified by screening monoclonal antibodies derived
from clonally expanded plasma blast populations from the cerebrospinal fluid of patients
with NMO160. The antibody Fc region was mutated to abolish its complement-dependent
and cell-dependent cytotoxicity functions139. The figure (right panel) shows the antibody
structure, with heavy (VH) and light (VL) chain variable regions, light chain constant
region (CL), and heavy chain constant regions (CH1–CH3). The mutations L234A and
L235A in Fc abolished antibody cytotoxicity effector functions. Because of the large size
of aquaporumab compared with AQP4, aquaporumab competes with the binding of
pathogenic, polyclonal AQP4-specific antibodies in NMO, preventing astrocyte
cytotoxicity and downstream inflammation and demyelination, as demonstrated in ex
vivo and in vivo mouse models of NMO. An alternative approach to aquaporumab
involves enzymatic deglycosylation of a patient’s own AQP4-specific IgG to render it
non-pathogenic141. Endoglycosidase S is a bacterial enzyme that selectively cleaves
glycans on residue N297 of IgG heavy chains (shown in the right panel of the figure).
This enzyme was shown to render patient AQP4-specific IgG non-pathogenic without
affecting AQP4 binding, thus converting a pathogenic antibody to a therapeutic blocking
antibody. A third approach involves small drug-like molecules, which are identified by
high-throughput screening, that bind to the extracellular surface of AQP4 and compete
with patient AQP4-specific IgG140.
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Conclusions
The field of AQP neuroscientific research has advanced remarkably in the past decade.
Important discoveries that could not have been predicted from the known function of AQPs
as water channels include the discovery of AQP4-specific antibodies and their role in
inflammatory demyelination, and the role for AQPs in cell migration. Despite these
advances, there remain many questions about the cellular mechanisms of AQP functions in
the nervous system and areas for further investigation. AQP-selective inhibitors are badly
needed as research tools to determine whether the various phenotypes that are seen in AQP
knockout mice are bona fide, isolated effects of loss of AQP function rather than secondary
effects of gene knockout. For example, it is unclear whether loss of AQP4 water transport
function is directly responsible for defective neuroexcitation and brain water clearance in
knockout mice, or whether these phenotypes are secondary to an expanded ECS or changes
in the expression of non-Aqp genes. The possible functions of AQPs in the peripheral and
enteric nervous systems, and in associated diseases, also need to be investigated. Further
study is also warranted into the possible involvement of AQP1 and AQP3 in intervertebral
disc hydration and spinal mechanics, and in clinical disc dehydration and degeneration.
Notwithstanding these gaps in our understanding of the functions and cellular mechanisms
of AQP involvement in nervous system function, there are compelling opportunities to
translate bench neuroscience into therapeutics, particularly in the areas of brain tumours,
neuroinflammation, cerebral and spinal cord oedema and, potentially, pain, epilepsy and
stroke. It is unlikely that AQP4 genetic variability has a major role in human diseases, as
AQP4 polymorphisms do not appear to have a causative role in NMO142, brain oedema after
middle cerebral artery stroke143 and temporal lobe epilepsy144. Continued advances are
anticipated in our understanding of the cellular mechanisms of AQP function, as well as in
AQP-targeted small-molecule therapeutics and biologics for the treatment of neurological
disorders.
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Glossary
α-syntrophin An intracellular protein that may form a complex with
aquaporin 4
Agrin A proteoglycan attached to extracellular matrix that may
anchor aquaporin 4 in the membrane
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Glial-limiting membrane This is the interface between the brain and the surrounding
cerebrospinal fluid, and comprises astrocyte processes
Circumventricular
organs
These are regions of the brain near ventricles that lack the
blood–brain barrier
Choroid plexus An intraventricular epithelial structure that secretes
cerebrospinal fluid
Tanycytes These are elongated cells that project from the third ventricle
to the hypothalamus
Ruffini
mechanoreceptors
These are skin mechanoreceptors
Müller cells These are aquaporin 4-expressing retinal glial cells
Claudius cells These are supporting cells (non-excitable cells) in the inner
ear
Hensen cells These are supporting cells (non-excitable cells) in the inner
ear
Inner sulcus cells These are supporting cells (non-excitable cells) in the inner
ear
Cytotoxic oedema This is the intracellular accumulation of excess water (cell-
swelling oedema)
Vasogenic oedema This is the interstitial accumulation of excess brain water
(leaky-vessel oedema)
Ependyma A membrane of epithelial cells lining the ventricles
Kaolin This is aluminium silicate that causes obstructive
hydrocephalus when injected into the cisterna magna of
rodents
Lamellipodia Projections at the front end of a migrating cell
Glioblastoma
multiforme
This is a highly infiltrative, malignant tumour of astrocytes
C5b–C9 complexes Cell plasma membrane pores composed of the complement
proteins C5b, C6, C7, C8 and C9. Deposition of enough
pores causes cell lysis
Plasma blast Upon activation by T helper cells, B cells differentiate into
plasma cells that secrete high levels of antibody. Plasma
blasts are the most immature plasma cells
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Figure 1. Sequence and structural features of AQP4
a | The schematic depicts the primary amino acid sequence and membrane topology of
aquaporin 4 (AQP4). This AQP has eight membrane-embedded helical segments, which are
labelled M1–M8, and two translation initiation sites — Met1 and Met23 (black) —
corresponding to the two AQP4 isoforms, M1 and M23, respectively. AQP4 tetramers can
form orthogonal arrays of particles (OAPs) through intermolecular N-terminal associations
between M23 isoforms involving the residues highlighted in purple. The residues in green
prevent N-terminal associations between M1 AQP4 molecules. Cysteine residues (in blue)
are sites of palmitoylation, and are involved in regulating OAP assembly. The C terminus of
AQP4 contains a PDZ domain (in green) that may be involved in protein–protein
interactions. b | X-ray crystal structure of human AQP4 (RCSB Protein Data Bank ID:
3GD8) shows the eight membrane-embedded helical segments. c | Freeze-fracture electron
micrograph (FFEM) of M23-AQP4-expressing Chinese hamster ovary cells shows that
AQP4 OAPs are supermolecular assemblies that have a cobblestone-like array structure (left
panel)14. The middle panel shows a super-resolution micrograph, which was obtained by
direct stochastic optical reconstruction microscopy (dSTORM), of cells co-expressing a
green fluorescent variant of M23-AQP4 and a red fluorescent variant of M1-AQP4 (REF.
18). From such micrographs, it has been determined that OAPs have a M23-AQP4-enriched
core, with M1-AQP4 being found in the periphery of these structures (diagrammatically
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depicted in the inset on the right). The left panel of part c is reproduced, with permission,
from REF. 14 © (1996) American Society for Biochemistry and Molecular Biology. The
middle and right panels in part c are modified, with permission, from REF. 18 © (2012) The
Company of Biologists Ltd.
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Figure 2. Aquaporin expression in the nervous system
a | In the retina, aquaporin 4 (AQP4) is expressed in its vitreous-facing ciliary epithelium
and in perivascular processes of Müller cells. b | In the olfactory epithelium, AQP4 is
expressed in olfactory epithelium support cells. c | In the inner ear, AQP4 can be detected in
the inner sulcus, and in Claudius and Hensen cells in the cochlea, and AQP1 can be found in
intermediate cells and fibrocytes of the spiral ligament. d | In the brain, AQP4 is primarily
expressed in astrocyte processes of the glia limitans externa and perivascular astrocyte foot
processes. AQP4 is also expressed in the basolateral cell plasma membrane of ependymal
cells and in subependymal astrocyte processes of the glia limitans externa. AQP1 is
expressed in the cerebrospinal fluid (CSF)-facing plasma membrane of the choroid plexus
epithelium. The sites of AQP9 expression remain unclear. e | In the spinal cord, AQP1 is
expressed in non-myelinated dorsal root ganglion (DRG) neurons, whereas AQP4 is
expressed in astrocyte processes of the glia limitans externa and in perivascular astrocyte
foot processes. f | In the enteric nervous system, AQP1 is expressed in glia, whereas AQP4
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is found in neurons and glia of the submucosal and myenteric plexuses. g | In the spine,
AQP9 is expressed in osteoclasts within the vertebrae, and AQP1 and AQP3 are found in
nucleus pulposus cells.
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Figure 3. Routes of water flow into and out of the CNS in brain oedema
In cytotoxic oedema, water enters the CNS through aquaporin 4 (AQP4) that is located in
perivascular astrocyte foot processes. In vasogenic oedema, CNS water entry is AQP4-
independent and occurs through intercellular spaces. In hydrocephalic oedema, water enters
the brain through AQP4 in ependymal cells and subependymal astrocytes. Oedema fluid is
eliminated through three AQP4-dependent routes: from astrocyte foot processes into the
bloodstream, across subpial astrocyte processes and pial cells into subarachnoid
cerebrospinal fluid (CSF), and across subependymal astrocyte processes and ependyma into
ventricle.
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Figure 4. Aquaporin 4 involvement in astrocyte migration and neuroexcitation
a | Aquaporin 4 (AQP4) has a proposed role in astrocyte migration. Water is driven into the
cytoplasm primarily through AQP4 in the lamellipodium by an osmotic gradient created by
actin depolymerization and active solute influx (left), facilitating lamellipodial extension in
the direction of cell migration (right). b | AQP4 is also proposed to have a role in
neuroexcitation outside the synaptic cleft (left panel). Neuroexcitation involves isosmolar
K+ release by neurons and uptake of K+ and water by astrocytes (centre panel). AQP4
facilitates water entry into astrocytes, resulting in contraction of the extracellular space
(ECS) volume and increased ECS K+ concentration ([K+]; right panel), which further drives
astrocyte K+ uptake.
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Figure 5. Proposed role of aquaporin 4 in the pathogenesis of neuromyelitis optica
a | Circulating aquaporin 4 (AQP4)-specific immunoglobulin G (IgG) enters the CNS and
binds to AQP4 on astrocyte foot processes. Complement is activated via the classical
pathway with deposition of C5b–C9 complexes in astrocyte cell plasma membranes. b |
Activated complement components attract peripheral leukocytes (primarily neutrophils and
eosinophils) into the lesion, which degranulate, causing astrocyte death. c | Chemokines
(from dying astrocytes and activated leukocytes) attract macrophages, causing death of
oligodendrocytes and neurons. d | Microglia enter the lesion as well as reactive astrocytes,
which express AQP4 and form a glial scar. The lesion core is necrotic with a macrophage
infiltrate.
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